Trial Information
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2- Negative, Locally Advanced nresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
